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E-mail addresses: boycerd@upmc.edu, rdb20@pitt.We describe a novel experiment that we conducted with the Drug Interaction Knowledge-base (DIKB) to
determine which combinations of evidence enable a rule-based theory of metabolic drug–drug interac-
tions to make the most optimal set of predictions. The focus of the experiment was a group of 16 drugs
including six members of the HMG-CoA-reductase inhibitor family (statins). The experiment helped iden-
tify evidence-use strategies that enabled the DIKB to predict signiﬁcantly more interactions present in a
validation set than the most rigorous strategy developed by drug experts with no loss of accuracy. The
best-performing strategies included evidence types that would normally be of lesser predictive value
but that are often more accessible than more rigorous types. Our experimental methods represent a
new approach to leveraging the available scientiﬁc evidence within a domain where important evidence
is often missing or of questionable value for supporting important assertions.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Our research focuses on how to best utilize drug-mechanism
knowledge to help drug interaction knowledge-bases expand their
coverage beyond what has been tested in clinical trials while
avoiding prediction errors that occur when individual drug differ-
ences are not recognized. Drug mechanism knowledge presents
difﬁcult informatics challenges because it is often dynamic, fre-
quently uncertain, and sometimes missing. A previous publication
by our group describes a novel evidential knowledge-representa-
tion approach that we designed to address these issues [1]. We
have implemented the approach in a system called the Drug Inter-
action Knowledge-base (DIKB) and have used the system to repre-
sent drug-mechanism evidence for 16 drugs including six
members of the HMG-CoA-reductase inhibitor family (statins) [2].
An intriguing feature of the DIKB’s knowledge-representation
approach is that it enables exploration of the empirical prediction
accuracy of a rule-based theory using many sub-sets of a given
body of evidence. We tested the usefulness of this feature for inte-
grating information from basic science, clinical research, and
authoritative statements for the purpose of making drug–drug
interaction (DDI) predictions. This paper brieﬂy reviews the knowl-
edge-representation approach implemented in the DIKB, detailsll rights reserved.
vilion, Suite 301-312E, 5150
2 623 7894/2814.
edu (R. Boyce).the methods and results of our novel experiment, and then dis-
cusses its implications for informatics and drug safety.
1.1. The DIKB’s evidential knowledge-representation approach
The DIKB is a knowledge representation system designed to
predict DDIs using drug mechanisms. A key component of the sys-
tem is a rule-based theory of how drugs interact by metabolic inhi-
bition. The system’s knowledge-base contains assertions about
speciﬁc entities such as drugs, drug metabolites, and enzymes
whose relationships with each other are more generally modeled
in the rule-based theory. DIKB maintainers place evidence for, or
against, each assertion in the system’s knowledge-base in an evi-
dence-base that is kept current by an editorial board. Before each
evidence item is entered into the system, maintainers identify its
type from a biomedical evidence taxonomy designed to have sufﬁ-
cient coverage of the kinds of evidence relevant for supporting or
refuting drug-mechanism assertions [2]. They then conﬁrm that
the evidence item meets explicitly deﬁned inclusion criteria that
apply to all evidence of its type.
The DIKB distinguishes between assertion instances and asser-
tion types. An assertion instance is a clear statement of some prop-
erty or relationship belonging to one or more entities while an
assertion type is the general form of all such instances. For exam-
ple, the generic (X substrate-of Y) is an assertion type describ-
ing a general relationship between an abstract drug and an abstract
enzyme. Instances of this assertion type might include assertions
Fig. 2. The 16 drugs and 19 drug metabolites chosen for DIKB experiments.
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rin substrate-of CYP2C9). Expert users map their conﬁdence in
drug-mechanism assertions by ﬁrst deﬁning combinations of evi-
dence types from the system’s evidence taxonomy that might sup-
port or refute instances of each assertion type. They then rank the
evidence-type combinations by the relative amount of conﬁdence
that they would have in an assertion instance of the given assertion
type if it were supported by the types of evidence present in the
deﬁnition. We call such rank-ordered combinations of evidence
types levels-of-evidence (LOEs).
For each assertion type in the system, expert users deﬁne two,
possibly identical, sets of LOEs; one for the types of evidence that
can support an assertion type, the other for the types of evidence
that refute it. They then select one LOE from each set of LOEs as
a belief criterion. Evidence against an assertion dominates evidence
for it hence, a query of the DIKB’s knowledge-base for valid drug-
mechanism assertions will return only those assertions whose
body of evidence for satisﬁes the belief criterion for supporting evi-
dence and whose body of evidence against does not satisfy the be-
lief criterion for refuting evidence. In this way, the system makes
DDI predictions using only those assertions considered current
by the system’s maintainers and believable by users.
1.2. The objective of an experiment with belief criteria
When drug experts deﬁne and rank LOEs or choose belief crite-
ria, they are making subjective judgements about the inferential
force of an abstract body of evidence. An important question is
whether the experts’ choices have any relationship to empirical
measures of the system’s performance. Fig. 1 deﬁnes four metrics
relevant to evaluating the DIKB—sensitivity, speciﬁcity, coverage,
and accuracy. Our hypothesis was that the system would have
poorer coverage but greater accuracy when using belief criteria
that inspire complete conﬁdence in a drug expert than when using
criteria that the expert believes to be less trustworthy. We based
this hypothesis on our intuition that the evidence types that ex-
perts consider less trustworthy are more readily available in the
literature, but often contain less generalizable scientiﬁc ﬁndings,
than types that the same experts view as more trustworthy.
We conducted an experiment to characterize the effect of vary-
ing belief criteria on the system’s accuracy and coverage of DDIs
present in a reference set of interactions and non-interactions.
The experiment was designed to answer the following research
questions:Fig. 1. The formulas in this ﬁgure deﬁne four of the metrics that were used t(1) What is the DIKB’s accuracy and coverage of reference set
interactions and non-interactions when using expert-
deﬁned belief criteria?
(2) Does changing the LOEs that are selected as belief criteria
alter the system’s prediction accuracy or coverage?
(3) Do computational experiments imply a particular belief crite-
ria strategy that optimizes the system’s prediction
performance?
2. Methods
2.1. Creation of the drug-mechanism knowledge-base
We collected sufﬁcient evidence on the pharmacokinetic drug
properties of 16 drugs and 19 drug metabolites to perform this
experiment. Fig. 2 lists the speciﬁc drugs and drug metabolites that
we chose to represent in the DIKB. The methods used to collect,
classify, and enter evidence into the DIKB are described in part I
of this two part series [2].
2.2. Creation of the experiment’s validation set
Once the evidence-base was complete except for minor
revisions, we attempted to identify all known pairwise metabolic
inhibition interactions and non-interactions between the 35 phar-
maceutical entities in the DIKB’s evidence-base. Our intent was
to use the interactions and non-interactions that we found as a val-
idation set for determining the accuracy and coverage of the DIKB’so characterize the performance of the DIKB using various belief criteria.
1 http://www.ncbi.nlm.nih.gov/PubMed/.
2 http://www.druginteractioninfo.org/.
3 http://www.dailymed.nlm.nih.gov.
992 R. Boyce et al. / Journal of Biomedical Informatics 42 (2009) 990–1003DDI predictions. The DIKB predicts interactions using knowledge of
drug mechanisms and a rule-based theory of how interactions oc-
cur by metabolic inhibition. The method that we used to conﬁrm
interactions and non-interactions approximated an independent
reference standard because it relied on quantitative observations
and did not consider underlying mechanisms.
We considered a metabolic inhibition interaction to be indepen-
dently conﬁrmed if any one of following criteria was satisﬁed:
(1) A pharmacokinetic DDI study provided data showing a sta-
tistically signiﬁcant (deﬁned below) increase in the Area
Under the concentration-time Curve (AUC) of the study’s
object drug or drug metabolite in the presence of the preci-
pitant drug or drug metabolite.
(2) An observation-based case report provided data showing a
measurable increase in the systemic concentration of a drug
or drug metabolite in the presence of another drug or drug
metabolite and the evidence board could ﬁnd no viable
alternate explanation for the observed increase.
We considered a metabolic inhibition non-interaction to be
independently conﬁrmed if all the following criteria were satisﬁed:
(1) A pharmacokinetic DDI study provided data showing no sta-
tistically signiﬁcant (deﬁned below) increase in the AUC of
the study’s object drug or drug metabolite in the presence
of the study’s precipitant drug or drug metabolite.
(2) None of the criteria listed above as independently conﬁrm-
ing a metabolic inhibition interaction was met.
If neither a metabolic inhibition interaction or non-interaction
could be conﬁrmed for any pair of pharmaceutical entities in the
DIKB then, we labeled the pair as having no known interaction or
non-interaction.
2.2.1. AUC ratios and statistical signiﬁcance
We deﬁned a statistically signiﬁcant increase in AUC to be:
AUCi
AUC
> 1:0 ðp 6 :05Þ ð1Þ
Where AUC is the baseline AUC for a DDI study’s object drug or drug
metabolite and AUCi is the AUC for the object drug in the presence
of the study’s precipitant drug or drug metabolite. Often studies do
not provide p-values, in such cases we judged an AUC increase sta-
tistically signiﬁcant if the study provided 95% conﬁdence intervals
for the AUC ratio AUCiAUC
 
that did not include 1.0. If the study’s results
did not satisfy Eq. (1), and/or the 95% conﬁdence intervals for the
AUC ratio (if available) included 1.0 then, we deﬁned the metabolic
inhibition interaction to not be statistically signiﬁcant.
2.2.2. Inclusion criteria for validation-set data
We sought evidence for conﬁrming interactions and non-inter-
actions from three sources of pharmacokinetic data—published
research articles, drug-product labeling, and published observa-
tion-based case reports. If the data came from a research article
then, the study must have satisﬁed the deﬁnition and inclusion cri-
teria of the evidence type A DDI clinical trial or any of its sub-types
in the DIKB evidence taxonomy (Appendices A and B, Supplemen-
tary material). If we found the data in drug-product labeling then it
must have met the inclusion criteria for the DIKB evidence type A
non-traceable drug-label statement (Appendix B, Supplementary
material). Finally, case reports needed to meet the inclusion crite-
ria for evidence of their type listed in Appendix B (Supplementary
material) and provide quantitative measurements of the systemic
concentration of the purported object drug before and after admin-
istration of the purported precipitant drug.2.2.3. The collection of pharmacokinetic data
We designed criteria for conﬁrming or refuting a metabolic-
inhibition DDI before we began collecting evidence. Once the
DIKB’s evidence-base was complete, we began building the valida-
tion set. We started by enumerating all ordered pairwise combina-
tions of the 35 drugs and drug metabolites in the DIKB’s ﬁnal
evidence-base. We used a single label in the validation set to rep-
resent both possible ways that an interaction might occur between
a drug or drug-metabolite pair. For example, assuming two drugs X
and Y, we used a single label X–Y to represent two possible inter-
actions—that X effects a change in the systemic concentration of Y
and vice versa. This resulted in a total of 595 labels (Eq. (2)) exclud-
ing same-compound combinations (e.g. simvastatin–simvastatin).
Appendix C (Supplementary material) lists 595 labels representing
all 1190 potential pairwise interaction and non-interactions be-
tween the drugs and drug metabolites in the DIKB.
35  34=2 ¼ 595 ð2Þ2.2.4. Avoiding biased measures of the DIKB’s accuracy
Throughout the evidence collection process we often found
clinical trials providing data that were relevant to both establishing
the validity of an assertion about some metabolic property and
conﬁrming a metabolic interaction or non-interaction. To avoid
biasing the validation set, we ﬁrst entered evidence items that
could be applied to both the DIKB’s evidence-base and the valida-
tion set in both places. Then, before assessing the system’s accu-
racy, we identiﬁed any evidence item that supported a claim
made by the validation set and was also used to support a DIKB
assertion that could lead to the same conclusion. We dropped from
further analysis the interaction or non-interaction that such evi-
dence supported. In total, seven pairs were dropped from further
analysis for this reason. These seven drug/drug or drug/drug-
metabolite pairs are shown in Table S1 (Supplementary material)
along with two other pairs that were accidentally excluded from
the experiment described in this paper due to a transcription error.
Excluding these nine pairs brought the total number of drug/drug
and drug/drug-metabolite pairs used for characterizing the DIKB’s
accuracy down to 586.
2.2.5. Searching for validation-set DDIs in the primary literature and
drug-product labeling
We searched the primary literature for clinical trials involving
any of the 586 drug/drug and drug/metabolite pairs in Appendix
C (Supplementary material) by querying PubMed1 and the proprie-
tary University of Washington Metabolism and Transport Drug Interac-
tion Database2 After completing an intensive search for all relevant
clinical trials, we conducted a search in drug-product labeling for
statements mentioning a pharmacokinetic interaction or non-inter-
action involving any of the 586 pairs. We searched all labels written
for each drug product whose only active pharmaceutical ingredient
was a drug in the DIKB. The number of qualifying product labels
for each drug ranged from one (atorvastatin, ﬂuvastatin, and rosu-
vastatin) to 18 (diltiazem) but a large proportion of the statements
in one product label were repeated in all of the other available labels.
All identiﬁed statements were noted and then ﬁltered so that only
statements providing quantitative data were used to support valida-
tion-set interactions. All searches were done using product labeling
in the NLM’s DailyMed database.3
In total, we found 65 drug-product labeling statements that
mentioned a pharmacokinetic interaction or non-interaction be-
tween the members of some drug or drug-metabolite pair included
Table 1
The 41 validation-set interactions that were used to characterize the DIKB’s prediction
performance. Asterisks indicate the object of a metabolic inhibition interaction
occurring between the pair. —the noted interaction occurs by inhibition of the
metabolic clearance of a parent compound.
Pair Source
alprazolam*–erythromycin [29]
alprazolam*–itraconazole [30]
alprazolam*–ketoconazole [31,32]
alprazolam*–nefazodone [33,34]
atorvastatin*–erythromycin [35]
atorvastatin*–nefazodone [36]
clarithromycin–atorvastatin* [37,38]
clarithromycin*–ﬂuconazole [39]
clarithromycin–pravastatin* [38]
diltiazem–beta-OH-lovastatin* [40]
diltiazem–lovastatin* [41]
diltiazem–midazolam* [42]
diltiazem–simvastatin* [43]
diltiazem–triazolam* [44]
erythromycin–beta-OH-simvastatin* [45]
erythromycin–simvastatin* [45]
ﬂuconazole–10-OH-midazolam*, [46]
ﬂuconazole–ﬂuvastatin* [47]
itraconazole–atorvastatin* [48]
itraconazole–beta-OH-lovastatin* [10]
itraconazole*–erythromycin [49]
itraconazole–lovastatin* [10]
itraconazole–ortho-OH-atorvastatin*, [48]
itraconazole–pravastatin* [48]
itraconazole–rosuvastatin* [14]
ketoconazole–simvastatin* [50]
midazolam*–clarithromycin [51,52]
midazolam*–erythromycin [53]
midazolam*–ﬂuconazole [46,54]
midazolam*–itraconazole [55]
midazolam*–ketoconazole [55]
midazolam*–nefazodone [56]
nefazodone–4-OH-alprazolam*, [34]
nefazodone–beta-OH-simvastatin* [36]
nefazodone–simvastatin* [36]
triazolam*–clarithromycin [17]
triazolam*–erythromycin [57]
triazolam*–ﬂuconazole [58]
triazolam*–itraconazole [59,60]
triazolam*–ketoconazole [60,61]
triazolam*–nefazodone [62]
Table 2
The seven validation-set non-interactions that we used to characterize the DIKB’s
prediction performance. Asterisks indicate which drug or drug metabolite should not
be affected by a metabolic inhibition interaction involving the other drug in the pair.
Pair Source
diltiazem–pravastatin* [41]
erythromycin–rosuvastatin* [8]
ﬂuconazole–14-OH-clarithromycin* [39]
ﬂuconazole–pravastatin* [47]
ﬂuconazole–rosuvastatin* [13]
itraconazole–ﬂuvastatin* [10]
nefazodone–pravastatin* [36]
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Table S2 (Supplementary material). Only 21 statements (31%)
reported the quantitative results of a pharmacokinetic clinical trial.
We approved these 21 for use in the validation set; the remaining
44 statements were retained so that drug-product labeling, clinical
trial literature, and case reports could be compared for their agree-
ment on validation-set interactions and non-interactions at a later
time.
2.2.6. Searching for validation-set DDIs in case report literature
Having completed searches within clinical trial literature and
drug-product labeling, we then did an intensive search of the Uni-
versity of Washington Metabolism and Transport Drug Interaction
Database and PubMed for published case reports claiming the
occurrence of a DDI between any pair of the active ingredients or
metabolites in our study. This search resulted in 35 relevant case
reports. We evaluated the full-text article for each of the 35 reports
to see if it met the pre-deﬁned inclusion criteria. Unfortunately,
none of the 35 reports was accepted for use in the validation set.
We rejected most case reports because they did not provide quan-
titative measurements of the systemic concentration of the pur-
ported object drug before and after administration of the
purported precipitant drug. Three case reports provided adequate
measurements of systemic concentration but failed to meet inclu-
sion criteria by not receiving a causation rating of at least ‘‘proba-
ble” when co-investigator J.H. assessed the report using Drug
Interaction Probability Scale [3]. Table S3 (Supplementary mate-
rial) cites the reports and provides an explanation for their low
causation score.
2.2.7. The ﬁnal validation set
The interactions and non-interactions in the ﬁnal validation set
are shown in Tables 1 and 2. The validation set claims that some
DDI will occur by metabolic inhibition for 41 drug/drug and
drug/drug-metabolite pairs and that no DDI will occur by meta-
bolic inhibition for seven pairs. No interaction or non-interaction
could be identiﬁed for 538 pairs in the validation set (Appendix
C, Supplementary material). It is important to stress that many of
these pairs might have clinically-relevant DDIs that were missed
by our evidence collection process or that have not been reported
in the sources we searched.
2.3. The creation of prediction sets for the experiment
2.3.1. Expert-deﬁned belief criteria
Once work on the evidence-base and validation set was com-
plete, the two drug experts in our group (C.C. and J.H.) then de-
ﬁned one or more LOEs for each assertion type. This was a two
step process; co-investigator R.B. (an informaticist) ﬁrst identi-
ﬁed all evidence types from the DIKB’s evidence taxonomy
(Appendix A, Supplementary material) that were applicable to
each assertion type. He then helped the two drug experts decide
the degree of certainty they would have in an assertion instance
whose evidence support consisted of the evidence items
represented by each evidence type or combination of evidence
types.4
2.3.2. The drug experts’ levels-of-evidence and ranking categories
Table 3 shows the set of labels, or ranking categories, that the
drug experts used deﬁne LOEs. Some labels in Table 3 represent
multiple evidence types that the drug experts believed would con-
fer roughly the same degree of justiﬁcation for drug-mechanism4 The questionnaire shown in Appendix G (Supplementary material) was used to
help the experts reach consensus on the inductive strength of each evidence-type
combination.assertions. The experts felt that several evidence types would not
be useful for supporting or refuting particular assertion types.
These evidence types were grouped into a special ‘‘not applicable”
ranking category and inserted as the lowest-ranking level-of-evi-
dence for the assertion type’s LOE.
While LOEs were designed separately for each assertion type,
many of the resulting LOEs were alike. As a result, only 15 LOEs
were deﬁned for the 22 assertion types in the DIKB’s rule-based
theory of metabolic drug–drug interactions. Table 4 enumerates
the assertion types that share the same LOEs. The symbols for each
LOE in Table 4 are used in Table 5 to show a concise overview of the
Table 3
This table shows the set of labels, or ranking categories, that the drug experts used deﬁne LOEs. Note: multiple evidence types that the drug experts thought would confer roughly
the same degree of justiﬁcation for drug-mechanism assertions are represented by a single label. —a ranking category created to represent evidence types that the drug experts
felt would not be applicable to supporting or refuting particular assertions.
Ranking category Evidence types
In vitro categories
iv-met-enz-id-Cyp-450-with-inh A CYP450, recombinant, drug metabolism identiﬁcation experiment using chemical inhibitors
A CYP450, human microsome, drug metabolism identiﬁcation experiment using chemical inhibitors
A CYP450, recombinant, drug metabolism identiﬁcation experiment using antibody inhibitors
A CYP450, human microsome, drug metabolism identiﬁcation experiment using antibody inhibitors
iv-met-enz-id-Cyp-450-recombinant A CYP450, recombinant, drug metabolism identiﬁcation experiment with possibly NO probe enzyme inhibitor(s)
iv-met-enz-id-Cyp-450-microsomal A CYP450, human microsome, drug metabolism identiﬁcation experiment
iv-met-inh-recombinant A CYP450, recombinant, metabolic enzyme inhibition experiment
iv-met-inh-microsomal A CYP450, human microsome, metabolic enzyme inhibition experiment
Clinical trial categories
pk-ct-pk A randomized DDI clinical trial
A genotyped pharmacokinetic clinical trial
A phenotyped pharmacokinetic clinical trial
pk-ct-pk-genotype A genotyped pharmacokinetic clinical trial
pk-ct-pk-phenotype A phenotyped pharmacokinetic clinical trial
pk-ddi-non-rndm A non-randomized DDI clinical trial
A parallel groups DDI clinical trial
pk-ddi-rndm A randomized DDI clinical trial
Statement categories
label-statement A non-traceable drug-label statement
nt-statement A non-traceable, but possibly authoritative, statement
Observation-based categories
obs-eval A published and evaluated observation-based ADE report
‘‘not applicable” categories
na-primary-total-clearance-enz A non-traceable, but possibly authoritative, statement
na-primary-metabolic-clearance-enzyme A CYP450, human microsome, drug metabolism identiﬁcation experiment using chemical inhibitors
na-substrate-of A CYP450, recombinant, drug metabolism identiﬁcation experiment with possibly NO probe enzyme inhibitor(s)
Table 4
While LOEs were designed separately for each assertion type, many of the resulting
LOEs were alike. As a result, only 15 LOEs were deﬁned for the 22 assertion types in
the DIKB’s rule-based theory of metabolic drug–drug interactions. This table
enumerates the assertion types that share the same LOEs.
LOE ID Applies to
A bioavailability
maximum-concentration
B first-pass-effect
fraction-absorbed
C primary-total-clearance-mechanism
D controls-formation-of
substrate-of
is-not-substrate-of
E primary-total-clearance-enzyme
F primary-metabolic-clearance-enzyme
G has-metabolite
H inhibition-constant
I inhibits
J does-not-inhibit
K does-not-permanently-deactivate-catalytic-function
permanently-deactivates-catalytic-function
in-vitro-probe-substrate-of-enzyme
L in-vitro-selective-inhibitor-of-enzyme
M in-viVo-selective-inhibitor-of-enzyme
sole-PK-effect-alter-metabolic-clearance
N pceut-entity-of-concern
O polymorphic-enzyme
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LOE is given in Table S4 (Supplementary material).2.3.3. The drug-experts’ belief criteria strategy
Once they had deﬁned a complete set of LOEs, the drug experts
selected two LOEs for each assertion type as its belief criteria; one
for evidence supporting an assertion and the other for evidence
refuting an assertion (see Table 6). The experts’ belief criteria strat-
egy used the top level-of-evidence from every LOE deﬁnition and,
therefore, was the most stringent one tested.
2.3.4. Automatically-generated belief criteria strategies
We expanded the DIKB so that it could make interaction and
non-interaction predictions using every belief criteria strategy pos-
sible with the expert-deﬁned LOEs. We were now able to charac-
terize the effect of varying belief criteria on the system’s
accuracy and coverage.
A default assumption is a special kind of assertion that is consid-
ered justiﬁed with no evidence support and that can be asserted or
retracted either manually by curators or automatically by the sys-
tem as it proceeds with inference. Initially, we were going to gen-
erate all belief criteria strategies by varying the LOEs chosen as
belief criteria for every assertion type that was not labeled as a de-
fault assumption. We excluded default assumptions because vary-
ing their belief criteria has no effect on the DIKB’s predictions.
Table 7 lists the set of assertion types not labeled as default
assumptions along with the number of LOEs that the evidence-
board deﬁned for each of them. As Eq. (3) shows, the total number
of belief criteria strategies that the DIKB would have generated for
these assertion types is 576,000.
53  42  32  25 ¼ 576;000 ð3Þ
However, inspection of the DIKB’s evidence-base revealed that
there were six assertion types for which all of the evidence items,
for or against, belonged to the highest-ranked LOE for the type. This
meant that varying the LOE chosen as a belief criterion for any of
these types (see Table 7) would have no effect on the DIKB’s predic-
Table 5
The symbols for each LOE in Table 4 are used in this table to show a concise overview of the ranking categories used for all LOEs. While an explicit deﬁnition of each LOE is given in
Table S4 (Supplementary material), it is possible to derive the same deﬁnitions from the columns in this table. For example, the column for LOE-1 shows that the LOE for group ‘‘A”
(Table 4) consists of the evidence types represented by two ranking categories (Table 3): pk-ct-pk and label-statement.
Ranking category LOE-1 LOE-2 LOE-3 LOE-4 LOE-5
pk-ct-pk A,B,C,G
pk-ct-pk-genotype D,E,F,O
pk-ct-pk-phenotype D,E,F,O
pk-ddi-rndm I,M,N D,E,F,J
pk-ddi-non-rndm I,N D,E,F,J,M
iv-met-enz-id-Cyp-450-with-inh G D
iv-met-enz-id-Cyp-450-recombinant K
iv-met-enz-id-Cyp-450-microsomal K
iv-met-inh-recombinant H,J,L I
iv-met-inh-microsomal H,J I,L
label-statement A,N B,C,H,I,J,K,O E,F,G,L,M D
nt-statement N K, O L,M
obs-eval N
na-primary-total-clearance-enz C
na-primary-metabolic-clearance-enzyme F
na-substrate-of G D
Table 6
This table shows the evidence-board’s belief criteria strategy. The columns next to each assertion type indicate the LOE group and speciﬁc LOE that the evidence-board chose as
the type’s belief criteria. There are two columns because the DIKB allows the belief criterion for supporting evidence to be different than the belief criterion for refuting evidence.
Note that the belief criterion for supporting evidence is the same as the belief criterion for refuting evidence for all but the inhibits and does-not-inhibit assertion types.
Assertion types indicated as default assumptions are noted separately because the system uses them for inference even if their evidence does not meet belief criteria.
Assertion type Evidence for Evidence against
Assertion types not used as default assumptions
bioavailability A, LOE-1 A, LOE-1
maximum-concentration A, LOE-1 A, LOE-1
first-pass-effect B, LOE-1 B, LOE-1
fraction-absorbed B, LOE-1 B, LOE-1
primary-total-clearance-mechanism C, LOE-1 C, LOE-1
controls-formation-of D, LOE-1 D, LOE-1
substrate-of D, LOE-1 D, LOE-1
is-not-substrate-of D, LOE-1 D, LOE-1
primary-total-clearance-enzyme E, LOE-1 E, LOE-1
primary-metabolic-clearance-enzyme F, LOE-1 F, LOE-1
has-metabolite G, LOE-1 G, LOE-1
inhibition-constant H, LOE-1 H, LOE-1
inhibits I, LOE-1 J, LOE-1
does-not-inhibit J, LOE-1 I, LOE-1
Assertion types used as default assumptions
permanently-deactivates-catalytic-function K, LOE-1 K, LOE-1
does-not-permanently-deactivate-catalytic-function K, LOE-1 K, LOE-1
in-vitro-probe-substrate-of-enzyme K, LOE-1 K, LOE-1
in-vitro-selective-inhibitor-of-enzyme L, LOE-1 L, LOE-1
in-viVo-selective-inhibitor-of-enzyme M, LOE-1 M, LOE-1
sole-PK-effect-alter-metabolic-clearance M, LOE-1 M, LOE-1
pceut-entity-of-concern N, LOE-1 N, LOE-1
polymorphic-enzyme O, LOE-1 O, LOE-1
5 www.python.org.
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assertion types labeled as default assumptions meant that there
were eight assertion types for which varying the LOE chosen as a
belief criterion would have an effect on prediction performance.
The DIKB generated all 36,000 different belief criteria strategies
possible for the remaining eight assertion types by altering the LOEs
chosen as belief criteria. The 14 remaining assertion types used the
highest-ranking LOEs deﬁned for their types as belief criteria.
2.4. Statistical analysis and programming
We used the R statistical language [4] to calculate all descriptive
and performance statistics. Bruno Falissard’s psy package [5] was
used to calculate a three-valued Cohen’s kappa score as a measureof the degree over random chance to which the DIKB and valida-
tion set agreed on interactions, non-interactions, and unknowns.
Both R and the Python programming language5 were used exten-
sively to write various programs that aided our analysis.
3. Results
3.1. Predictions made using the drug-experts’ belief criteria strategy
We began the experiment by testing the accuracy and coverage
of the DIKB using the drug-experts’ belief criteria strategy (Section
Table 7
The set of assertion types whose validity in the DIKB’s knowledge-base is based on
evidence assessment. The assertion types are shown in decreasing order based on the
number of LOEs that we deﬁned for each of them. —an assertion type for which
varying the LOE chosen as a belief criterion would have no effect on the DIKB’s
prediction performance because all of the associated evidence was of a type belonging
to the highest-ranking LOE.
Assertion type LOE count
controls-formation-of 5
substrate-of 5
is-not-substrate-of 5
has-metabolite 4
primary-metabolic-clearance-enzyme 4
primary-total-clearance-enzyme 3
primary-total-clearance-mechanism 3
does-not-inhibit 2
first-pass-effect 2
fraction-absorbed 2
inhibition-constant 2
inhibits 2
maximum-concentration 1
bioavailability 1
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drug/drug-metabolite pairs would interact by metabolic inhibition
and that two would not (see Table 8). Fourteen interaction predic-
tions were present in the validation set and so were considered
true positives. The remaining interaction prediction and the two
non-interaction predictions were classiﬁed as ‘‘unknown” because
they were neither conﬁrmed nor refuted by the validation set.
The predicted pharmacokinetic magnitude of all 14 conﬁrmed
predictions corresponded with levels observed in clinical trial data.
While the system’s predictions and magnitude estimates using the
drug experts’ strategy had perfect accuracy, its coverage of known
interactionswas poor. Only 14 (34%) of the 41pairs known in the val-
idation set to interactbymetabolic inhibitionwerepredicted to inter-
act by the DIKB. Also, the system failed to predict any of the seven
pairs known in the validation set to not interact by the samemecha-
nism. The system’s poor coverage using the experts’ belief criteria
strategywas expected since itwas themost stringent strategy tested.Table 8
Seventeen interaction and non-interaction predictions made by the DIKB using the
evidence-board’s belief criteria strategy. Asterisks indicate the drug or drug metab-
olite that the system predicts will be the object of the interaction. The DIKB makes
interaction predictions at three levels representing the anticipated AUC ratio of the
DDI’s object drug: AUCiAUC ¼ ð0; 1:3Þ, AUCiAUC ¼ ½1:3; 2Þ, and AUCiAUC > 2. —a pair classiﬁed as
‘‘unknown” in the validation set. —AUC ratios present in at least one evidence item in
the validation set that supports the interaction.
Pair Prediction AUCi=AUC

diltiazem–midazolam* AUCi
AUC > 2 P 3
diltiazem–triazolam* AUCi
AUC > 2 2.83
midazolam*–clarithromycin AUCi
AUC > 2 P 7
midazolam*–erythromycin AUCi
AUC > 2 4.4
midazolam*–fluconazole AUCi
AUC > 2 P 2:6
midazolam*–itraconazole AUCi
AUC > 2 10.8
midazolam*–ketoconazole AUCi
AUC > 2 15.9
midazolam*–nefazodone AUCi
AUC > 2 4.6
triazolam*–clarithromycin AUCiAUC > 2 5.3
triazolam*–erythromycin AUCi
AUC > 2 2.1
triazolam*–fluconazole AUCi
AUC > 2 2.5
triazolam*–itraconazole AUCi
AUC > 2 P 3:1
triazolam*–ketoconazole AUCi
AUC > 2 P 9:2
triazolam*–nefazodone AUCi
AUC > 2 P 3:9
triazolam*–atorvastatin AUCi
AUC > 2 n/a
triazolam–simvastatin No interaction n/a
triazolam–beta-OH-simvastatin No interaction n/a3.2. Predictions made using the computer-generated belief criteria
strategies
We then analyzed the computer-generated belief criteria strat-
egies to see what inﬂuence they had on the accuracy and coverage
DIKB’s predictions. The DIKB failed to make any predictions using
one computer-generated strategy due to some unknown error that
occurred during the experiment. The results from this strategy
were not used in further analysis. We analyzed the remaining
35,999 different strategies for accuracy, coverage, and agreement
with the validation set. Table 9 shows summary statistics for each
performance parameter we analyzed over all prediction sets.
The DIKB’s sensitivity ranged from 0.88 to 1.0 with 19,583 (54%)
of the belief criteria strategies causing the system to operate at
maximum sensitivity. The systems speciﬁcity ranged from 0.0 to
1.0 with 6912 (19%) of the belief criteria strategies causing the sys-
tem to operate at maximum speciﬁcity. The system had excellent
positive predictive value (range: 0.94–1) across all belief criteria
strategies. However, we could not characterize the system’s nega-
tive predictive value in a meaningful way because the DIKB never
predicted more than two of the seven validation set non-interac-
tions using any belief criteria strategy. We also calculated three-
valued kappa scores for every prediction set using Cohen’s kappa
to see how the agreement between the DIKB and the validation
set compared with agreement expected by random chance. The
DIKB’s predictions across all prediction sets had moderate agree-
ment (0.4–0.5) with the validation set and never reached levels
typically considered indicative of signiﬁcant agreement (P 0:7).
It would be informative to show the trade-off in the true-positive
and false-positive rate of the DIKB over all belief criteria strategies
using a receiver operating characteristic (ROC) curve. However,
there is no way to create an ROC curve for the DIKB’s prediction sets
because LOEs are rank-ordered. Another issue is that the false-posi-
tive rate of the system can not be calculated for 28,511 strategies for
which the system made no true negative or false positive predic-
tions. Fig. 3 shows a scatter-plot of the DIKB’s true-positive rate ver-
sus its false-positive rate over the 7488 belief criteria strategies for
which a false-positive rate can be calculated. The plot shows that a
numberof strategies cause thesystemtomakeno falsepositivespre-
dictions with high, or nearly perfect, sensitivity.
Fig. 4 shows the accuracy and coverage of the DIKB as the pro-
portion of higher-ranking LOEs present in a belief criteria strategy
increases. To create the x axis for this plot, we ﬁrst assigned an
integer-rank to each level-of-evidence in the LOEs for the eight
assertion types for which varying belief criteria had an effect on
prediction performance (see Section 2.3.4). The integer-ranks were
assigned such that the highest-ranking level-of-evidence was as-
signed a one, the next a two, and so-on. Then, for all 35,999 belief
criteria strategies possible with the selected LOEs, the average inte-
ger-rank of each level-of-evidence used in the strategy was divided
into 1.0. The resulting metric has a range of 0.26 (least stringent) to
1.0 (most stringent) for the set of strategies used in the current
study. Fig. 4 indicates that the most stringent belief criteria strat-
egy resulted in very accurate predictions but that a large number
of less stringent strategies produced the same accuracy while cover-
ing a greater proportion of validation-set interactions. Fig. 5 shows
this ﬁnding more clearly by plotting, at four different stringency
levels, the proportion of belief criteria strategies that matched
the most stringent strategy’s accuracy but had better coverage.
A notable result of this experiment is that 8351 (23%) of the
35,599 tested strategies caused theDIKB to have equal or better per-
formance in terms of sensitivity, positive predictive value, and
agreement with the validation set than the most stringent strategy.
Table 10 shows the performance characteristics for 1152 (3%) strat-
egies that performed at the top level in these three performance cat-
egories. It is important to note that neither the most stringent
Table 9
Summary statistics for each performance parameter that we analyzed for all 35,599 belief criteria strategies. The columns labeled ‘‘n” show the number of strategies whose
predictions shared each minimum and maximum value.
Statistic Min n Median Mean Max n
True positives 14.0 1440 33.0 30.8 34.0 17,280
False positives 0.0 17,279 1.0 0.6 2.0 2880
True negatives 0.0 21,599 0.0 0.7 2.0 11,520
False negatives 0.0 19,583 0.0 0.6 2.0 4032
Sensitivity 0.88 576 1.00 0.98 1.00 19,583
Speciﬁcity 0.00 11,232 0.50 0.44 1.00 6912
Positive predictive value 0.94 240 0.97 0.98 1.00 17,279
DIKB-only unknown 10.0 5760 13.0 15.3 34.0 576
Validation-set-only unknown 3.0 864 40.0 42.4 62.0 2880
Kappa 0.41 576 0.47 0.48 0.52 768
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Fig. 3. The set of predictions that the DIKB makes is inﬂuenced by varying the LOEs
chosen as belief criteria for each assertion type. Since LOEs are rank-ordered there is
no way to create a continuous receiver operating characteristic (ROC) curve. This
ﬁgure shows a scatter plot of the true-positive rate (sensitivity) versus the false-
positive rate (1:0—speciﬁcity) over the 7488 belief criteria strategies for which both
values could be calculated. The system made no ‘‘true negative” or ‘‘false positive”
predictions using the strategy chosen by the drug experts so, its performance using
that strategy cannot be shown in the scatter-plot.
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Fig. 4. A scatter-plot of the accuracy and coverage of the DIKB as the proportion of
higher-ranking LOEs present in a belief criteria strategy increases. The vertical line
intersecting 1.0 on the x axis indicates the accuracy and coverage of the most
stringent belief criteria strategy that was deﬁned by the drug experts. The
numerical metric for stringency used in this plot (1.0/average LOE level) was
developed as follows: (1) An integer-rank was assigned to each level-of-evidence in
the LOEs for the eight assertion types for which varying belief criteria had an effect
on prediction performance. This was done such that the highest-ranking level-of-
evidence was assigned a one, the next a two, and so-on. (2) For all 35,999 belief
criteria strategies, the average integer-rank of each level-of-evidence used in the
strategy was divided into 1.0. The resulting metric has a range of 0.26 (least
stringent) to 1.0 (most stringent) for the set of strategies used in the current study.
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non-interactions that were conﬁrmed or refuted by the validation
set. Thismeant thatwe couldnot calculate the speciﬁcity of theDIKB
using either expert or computer-generated strategies.
All of the ‘‘best-performing” strategies caused the DIKB to make
the same set of 65 interaction and non-interaction predictions.
These strategies predicted a metabolic inhibition interaction for
34 (83%) of the 41 interacting pairs in the validation set while mak-
ing no false positive and no false negative predictions. The system’s
coverage of the validation set using any of these ‘‘best-performing”
strategies was incomplete—it made no predictions for seven inter-
actions and seven non-interactions listed in the validation set. As
Table 11 shows, the pharmacokinetic magnitude of 30 of the 34
conﬁrmed (88%) predictions made using the best-performing belief
criteria strategies matched levels observed in clinical trial data.
3.3. Evaluation of the DIKB’s novel DDI predictions made using the
best-performing belief criteria strategies
The system also predicted 31 metabolic inhibition interactions
and nine non-interactions using the 1152 ‘‘best-performing” beliefcriteria strategies whose validity was unknown by the validation
set. These novel interaction predictions (Table S5, Supplementary
material) represent potentially interacting drug combinations that
our review of the literature indicate have not been studied. We
searched PubMed for clinical trials involving these pairs and could
only ﬁnd one clinical trial that was not already included in the val-
idation set [6] unfortunately, this study did not meet the inclusion
criteria for its evidence type and so could not be used as evidence
for, or against, any interactions.
Fifteen of the published case reports we had collected while
constructing the validation set claimed the occurrence of a DDI
that matched one of the 31 novel predictions. Each report was re-
viewed using the Drug Interaction Probability Scale (DIPS) [3] by
clinician co-investigator J.H.. The DIPS deﬁnes four qualitative lev-
els (Doubtful, Possible, Probable, and Highly Probable) representing
the degree to which the information provided by the report sup-
ports the proposition that a speciﬁc drug combination effected an
adverse event or events. Six novel predictions were matched with
Matched Accuracy and beat Coverage
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Fig. 5. A barplot of the proportion of belief criteria strategies at four different
stringency levels that matched the accuracy but had better coverage than the most
stringent strategy. Fig. 4 explains the numerical metric for stringency that is used in
this plot. The plot makes it clear that less stringent strategies often result in a
greater coverage of known interactions with no loss of accuracy.
Table 11
Each of the 1152 strategies that caused the DIKB to perform optimally in terms of
sensitivity, positive predictive value, and agreement with the validation set caused
the system to make the same 34 interaction predictions that were conﬁrmed by the
validation set. Asterisks indicate the drug or drug metabolite that the system predicts
will be the object of the interaction. —the DIKB’s magnitude estimate did not
correspond with validation-set data —the DIKB also predicted a metabolic inhibition
interaction at the AUCiAUC ¼ ð0;1:3Þ level with clarithromycin as the object drug.
Pair DIKB AUCiAUC AUCi=AUC
alprazolam*–erythromycin ð0;1:3Þ 1.61
alprazolam*–itraconazole ð0;1:3Þ 2.7
alprazolam*–ketoconazole ð0;1:3Þ 3.98
alprazolam*–nefazodone ð0;1:3Þ 1.98
atorvastatin*–erythromycin > 2 1.4
atorvastatin*–nefazodone > 2 3-4
clarithromycin–atorvastatin*, > 2 P 1:8, max 5.4
clarithromycin*–ﬂuconazole > 0 P 1:18, max 1.33
diltiazem–lovastatin* > 2 P 3
diltiazem–beta-OH-lovastatin* > 2 3.57
diltiazem–midazolam* > 2 3.75
diltiazem–simvastatin* > 2 4.8
diltiazem–triazolam* > 2 2.83
erythromycin–simvastatin* > 2 6.3
erythromycin–beta-OH-simvastatin* > 2 3.9
ﬂuconazole–ﬂuvastatin* > 2 1.83
itraconazole–atorvastatin* > 2 2.5
itraconazole–lovastatin* > 2 14.8
itraconazole–beta-OH-lovastatin* > 2 8.56
ketoconazole–simvastatin* > 2 12.55
midazolam*–clarithromycin > 2 P 7
midazolam*–erythromycin > 2 4.4
midazolam*–ﬂuconazole > 2 P 2:6
midazolam*–itraconazole > 2 10.8
midazolam*–ketoconazole > 2 15.9
midazolam*–nefazodone > 2 4.6
nefazodone–simvastatin* > 2 20
nefazodone–beta-OH-simvastatin* > 2 20
triazolam*–clarithromycin > 2 5.3
triazolam*–erythromycin > 2 2.1
triazolam*–ﬂuconazole > 2 2.5
triazolam*–itraconazole > 2 P 3:1
triazolam*–ketoconazole > 2 P 9:2
triazolam*–nefazodone > 2 P 3:9
Table 12
The two novel interaction predictions shown in this table were supported by case
reports but were not present in any of the 65 drug–drug interaction statements from
product labeling that we had collected while building the validation set. Asterisks
indicate the interaction’s predicted object drug.
Predicted interaction DIKB AUCiAUC Report and DIPS score
diltiazem–atorvastatin* > 2 [63]:possible
ﬂuconazole–simvastatin* > 2 [64]:possible
Table 10
Belief criteria strategies (1152, 3%) caused the DIKB to perform optimally in terms of
sensitivity, positive predictive value, and agreement with the validation set as
measured by Cohen’s kappa. This table shows all measured performance character-
istics for these ‘‘best-performing” strategies.
Statistic Value Statistic Value
True positives 34 False positives 0
True negatives 0 False negatives 0
Sensitivity 1 Speciﬁcity n/a
Positive predictive value 1 Kappa 0.52
DIKB-only unknown 14 Validation-set-only unknown 40
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predicted interactions were the likely cause of an adverse event
occurring in a patient. Seven novel predictions were matched with
reports that met the DIPS Possible level; meaning that the predicted
interactions could not be excluded from consideration as the cause
of an adverse event in a patient.
3.4. Comparing the DIKB predictions to labeling statements
We could not do a quantitative comparison of the system’s pre-
dictions with drug–drug interaction statements from product
labeling because a signiﬁcant proportion of the validation set
was constructed from labeling statements. We examined the 44
statements that were not used in the validation set and found that
two of the seven novel predictions that were matched with reports
meeting the DIPS Possible level could not be inferred from any of
the product labeling statements (see Table 12). We believe that
the combination of evidence from the case report literature sup-
porting these interactions and the lack of discussion in drug-prod-
uct labeling makes these interactions especially important to
investigate further.
We also found one product label statement declaring an inter-
action that is refuted by clinical trial data present in the validation
set. This statement extrapolated an interaction observed between
erythromycin and one or more HMG-CoA reductase inhibitors to
all drugs in that class:Erythromycin has been reported to increase concentrations of
HMG-CoA reductase inhibitors (e.g., lovastatin and simvasta-
tin). Rare reports of rhabdomyolysis have been reported in
patients taking these drugs concomitantly [7].
The active ingredient rosuvastatin is among the HMG-CoA
reductase inhibitors included in our study. The labeling statement
indirectly declares a potential pharmacokinetic interaction be-
tween erythromycin and rosuvastatin that is refuted by a random-
ized clinical trial in the validation set [8]. None of the interaction
predictions made by the DIKB using the evidence board or the
best-performing belief criteria strategies were refuted by the
validation set (i.e. false positives or false negatives). While the sys-
tem made no prediction involving erythromycin and rosuvastatin
with these strategies, it correctly predicted a non-interaction be-
tween erythromycin and rosuvastatin using other belief criteria
strategies. These results indicate that, depending on belief criteria
R. Boyce et al. / Journal of Biomedical Informatics 42 (2009) 990–1003 999strategies, DDI prediction using drug-mechanism knowledge can
be accurate while avoiding the kinds of false predictions that occur
when individual drug differences are not recognized.4. Discussion
Changing the LOEs selected as belief criteria altered the sys-
tem’s prediction accuracy and coverage in the way that we had
hypothesized. We found for this data set that, as the criteria for
including assertions were relaxed, the DIKB predicted a larger
number of true interactions; sometimes at the expense of also
making more false predictions. By having the computer iterate
through a large set of possible belief criteria strategies we found
that a signiﬁcant proportion (23%) of them caused the DIKB to have
equal or better performance in terms of sensitivity, positive predic-
tive value, and agreement with the validation set than the most
stringent strategy designed by drug experts.
4.1. Further analysis of the ‘‘best-performing” strategies
The experiment also found a particular family of belief criteria
strategies that optimized the system’s prediction accuracy and
coverage. Table 13 shows the range of LOEs used by the 1152
‘‘best-performing” belief criteria strategies. To better understand
the information in Table 13, it is useful to note the situations where
a level-of-evidence can be selected as a belief criterion for an asser-
tion type without having any effect on the system’s predictions.
Any level-of-evidence can be chosen as a belief criterion for an
assertion type that is not relevant for the predictions-of-interest: In
the current study, the types substrate-of and inhibits were
key to making all interaction predictions. In contrast, one assertion
type, primary-metabolic-clearance-enzyme, was used
exclusively to predict the magnitude of an interaction. Varying this
assertion’s belief criteria could not affect the system’s non-magni-
tude predictions and, therefore, had no effect on the study’s perfor-
mance metrics. Indeed, Table 13 shows that all four of this
assertion type’s LOEs were used by the ‘‘best-performing”
strategies.
Any level-of-evidence can be chosen as a belief criterion for an
assertion type when there is no evidence that supports or refutes its
instances: Table 13 shows that there were multiple cases where
no evidence items were mapped to a particular level-of-evidence
for an assertion type. For example, since none of the 17 evidence
items that were linked to controls-formation instances map
to the assertion type’s top two ranking LOEs (D: LOE-1 and D:
LOE-2), the system’s predictions were not affected when either
was chosen as a belief criterion. Similar situations held for the
is-not-substrate-of, and primary-metabolic-clear-
ance-enzyme assertion types.
Choosing a lower-ranking level-of-evidence as a belief criterion has
no effect on predictions if all instances of an assertion type are justiﬁed
by a higher-ranking level-of-evidence: While the inhibits asser-
tion type was relevant for making DDI predictions, Table 13 shows
that both of its LOEs (I: LOE-1 and I: LOE-2) were used by the ‘‘best-
performing” belief criteria strategies. This was because there was
only one evidence item that mapped to LOE-2; an item supporting
the assertion (ketoconazole inhibits CYP3A4). The same
assertion had two other evidence items that mapped to LOE-1.
As a result, the assertion was justiﬁed no matter which LOE the
system chose as a belief criterion for the inhibits assertion type.
These observations suggest that the experiment’s ‘‘best-
performing” belief criteria strategies are quite likely unique to
the set of drugs and evidence items used in the current experi-
ment. For example, further work on the evidence-base might iden-
tify new evidence items that map to LOE-2 for the inhibitsassertion and that cause the system to make false predictions. Sim-
ilarly, the effect of evidence items that map to LOE-1 or LOE-2 for
the controls-formation assertion type are unknown because
such evidence was not present in the current evidence base. We in-
tend to explore if the ‘‘best-performing” strategies perform as well
for a different set of drugs and evidence items in future work.
4.2. Prediction sets that produced invalid predictions
So far in our discussionwe have focused only on the performance
of theDIKBusing the ‘‘best-performing” strategies. However, 27,648
(77%) of the strategies that we tested caused the DIKB to predict at
least one interaction or non-interaction considered invalid by the
validation set. The maximumnumber of interaction or non-interac-
tion predictions refuted by the validation set for any single strategy
was three and included either two invalid interactions and one inva-
lid non-interaction or vice versa. Table 14 shows the four invalid pre-
dictions that appeared in various combinations among the
predictions made using a wide range of strategies. We now brieﬂy
discuss the conditions under which each of these predictions were
made.
4.2.1. Invalid predictions caused by low-ranking evidence
itraconazole–ﬂuvastatin: The itraconazole–ﬂuvastatin interac-
tion prediction occurred when the system used strategies that ac-
cept drug labeling statements as belief criteria because (1) the
assertion (itraconazole inhibits CYP3A4) was a default
assumption and (2) the evidence-base recorded one labeling state-
ment (based on a non-cited in vitro study) proposing that CYP3A4 is
a minor elimination pathway for ﬂuvastatin (< 20% of total clear-
ance) [9]. This prediction was refuted in the validation set by a ran-
domized controlled trial involving 10 healthy volunteers that
showed no signiﬁcant increase in the systemic concentration of
ﬂuvastatin in the presence of itraconazole [10].
ﬂuconazole–rosuvastatin: The DIKB predicted the ﬂuconazole–
rosuvastatin interaction using strategies that allow statements in
product labeling to justify the controls-formation and has-
metabolite assertion types and non-randomized clinical trial
data to justify the inhibits assertion type. In this case, the sys-
tem inferred that rosuvastatin is a substrate-of CYP2C9 because
the two assertions (rosuvastatin has-metabolite N-desm-
ethylrosuvastatin) and (CYP2C9 controls-formation-of
N-desmethylrosuvastatin) were each supported by evidence
items based on labeling information [11] and the assertion
(fluconazole inhibits CYP2C9) was supported by a non-ran-
domized clinical trial [12]. This prediction was refuted in the vali-
dation set by a randomized controlled trial involving 14 healthy
volunteers that found no statistically signiﬁcant increase in the
systemic concentration of rosuvastatin in the presence of ﬂuconaz-
ole [13].
itraconazole–rosuvastatin: The DIKB predicted a non-interaction
between itraconazole and rosuvastatin via CYP3A4 inhibition using
strategies that allow statements in product labeling to justify the
is-not-substrate-of assertion type. This was because the evi-
dence-base contained one evidence item, based on a labeling state-
ment, declaring CYP3A4 to not have a role in the metabolic
clearance of rosuvastatin [11]. The validation set contained a ran-
domized clinical trial that found a small, but statistically signiﬁ-
cant, increase in the systemic concentration of rosuvastatin in
the presence of itraconazole during [14].
4.2.2. An invalid prediction caused by using more stringent LOEs
ﬂuconazole–clarithromycin: The system predicted a non-interac-
tion between ﬂuconazole and clarithromycin using strategies that
considered (1) inhibits type justiﬁed by non-randomized clinical
trial data, (2) the is-not-substrate-of assertion type justiﬁed
Table 13
This table shows the range of LOEs used by 1152 belief criteria strategies that had perfect sensitivity and positive predictive value and optimized the DIKB’s coverage and
agreement with the validation set. The LOEs that were chosen as belief criteria for supporting and refuting evidence were always the same for the assertions shown in the table.
The columns evidence for and evidence against show the distribution of evidence items across the LOEs. Not shown are the assertion types for which varying the LOEs chosen as
belief criteria would have no effect on the DIKB’s prediction performance (Section 2.3.4).
Assertion type Belief criteria Evidence
for
Evidence
against
inhibits I: LOE-1, LOE-2 n = 11  LOE-1(91%), LOE-2(9%) n = 4  LOE-1(50%), LOE-2(50%)
substrate-of D: LOE-3 n = 29  LOE-1(10%), LOE-2(21%), LOE-3(17%), LOE-
4(21%), LOE-5(31%)
n = 11  LOE-1(0%), LOE-2(0%), LOE-3(36%), LOE-
4(9%), LOE-5(55%)
is-not-substrate-of D: LOE-1? LOE-3 n = 11  LOE-1(0%), LOE-2(0%), LOE-3(36%), LOE-
4(9%), LOE-5(55%)
primary-total-
clearance-mechanism
C: LOE-1? LOE-3 n = 14  LOE-1(21%), LOE-2(64%), LOE-3(14%)
primary-total-
clearance-enzyme
E: LOE-3 n = 8  LOE-1(25%), LOE-2(62%), LOE-3(13%)
primary-metabolic-
clearance-enzyme
F: LOE-1? LOE-4 n = 3  LOE-1(0%), LOE-2(0%), LOE-3(67%),
LOE-4(33%)
n = 1  LOE-1(100%), LOE-2(0%), LOE-3(0%),
LOE-4(0%)
controls-formation-ofa D: LOE-1? LOE-3,
LOE-4, LOE-5
n = 17  LOE-1(0%), LOE-2(0%), LOE-3(12%),
LOE-4(6%), LOE-5(82%)
has-metabolitea G: LOE-1 ? LOE-2,
LOE-3, LOE-4
n = 27  LOE-1(19%), LOE-2(0%), LOE-3(44%),
LOE-4(37%)
a No belief criteria strategy in the set of 1152 used LOE-4 or any lower-ranking LOE for the controls-formation-of assertion type and LOE-3 or any lower-ranking LOE
for the has-metabolite assertion type.
Table 15
Pairs in the validation set (Tables 1 and 2) for which the DIKB made no prediction
using any the 35,599 belief criteria strategies.
Missing interactions Missing non-interactions
clarithromycin–pravastatin diltiazem–pravastatin
ﬂuconazole–10-OH-midazolam ﬂuconazole–pravastatin
itraconazole–pravastatin nefazodone–pravastatin
itraconazole–erythromycin ﬂuconazole–14-OH-clarithromycin
itraconazole–ortho-OH-atorvastatin
nefazodone–4-OH-alprazolam
Table 14
Strategies (27,648) led the DIKB to predict one or more of the interactions or non-
interactions shown in this table that were refuted by the validation set. For refuted
interactions, asterisks indicate the drug that the DIKB considers the object of a
metabolic inhibition interaction via the enzyme shown in parentheses. For refuted
non-interactions, they indicate the drug that should not be affected by inhibition of
the enzyme shown in parentheses.
Refuted interactions
itraconazole–ﬂuvastatin* (CYP3A4)
ﬂuconazole–rosuvastatin* (CYP2C9)
Refuted non-interactions
itraconazole–rosuvastatin* (CYP3A4)
clarithromycin*–ﬂuconazole (CYP2C9)
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somes and chemical inhibitors, and (3) the substrate-of asser-
tion type justiﬁed by any of the clinical trial types. These
strategies caused the system to apply one evidence item [12] to
justify the assertion (fluconazole inhibits CYP2C9) and an-
other item [15] to justify the assertion (clarithromycin is-
not-substrate-of CYP2C9).
This case is interesting because the invalid prediction was over-
ruled when using a less stringent levels-of-evidence for the sub-
strate-of assertion type. The ﬁrst two LOEs for the
substrate-of assertion type are deﬁned by various clinical trial
types. Strategies that used the assertion type’s third-ranking LOE,
in vitro metabolism identiﬁcation experiments, as belief criterion
predicted a validated interaction between ﬂuconazole and clari-
thromycin via CYP3A4 inhibition. We think that this case shows
the value of examining the performance of the system at all possi-
ble belief criteria strategies.
4.3. Why was the DIKB’s coverage of validation-set interactions
always incomplete?
Table 15 shows six interactions and four non-interactions pres-
ent in the validation set that were never predicted by the DIKB
using any belief criteria strategy. We now brieﬂy examine why
the system missed these interactions and non-interactions.Missing non-interaction involving pravastatin: The systemmissed
the non-interactions involving pravastatin because its evidence-
base was incomplete in regards to the pravastatin’s metabolic
properties. Although pravastatin’s drug-product label states that
it is not metabolized by CYP3A4 ‘‘to any signiﬁcant extent” [16],
this evidence was never entered into the DIKB. Doing so would
have caused the system to predict the three missing non-interac-
tions involving pravastatin using some belief criteria strategies.
This case shows that missing interactions and non-interaction
can help identify errors made while building the DIKB’s evi-
dence-base. We think that an analysis of missing interactions
and non-interactions should be done as quality assurance every
time a set of ‘‘best-performing” strategies is created for a new set
of drugs. Once errors are corrected, the process of identifying
‘‘best-performing” strategies can be repeated.
Missing interactions involving pravastatin: It is important to note
that entering the aforementioned product label evidence would
have caused the system to predict non-interactions for the two
missing interactions involving pravastatin (Table 15). If the non-
interaction predictions are incorrect then, the interactions likely
occur by mechanisms other than those modeled by the DIKB’s cur-
rent DDI theory. If these mechanisms are known then, the DDI the-
ory and evidence-base should be expanded to include them.
Another possible explanation is that non-interaction predictions
are correct, but that the studies that support the interactions con-
tain some limitation. In this situation, it would be important to
identify the limitation and integrate it into the inclusion criteria
used to collect evidence.
6 http://www.micromedex.com/products/drugdex/.
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ing interactions and one non-interaction are accounted for by the
fact thatwere no assertions in the system indicatingwhich enzymes
do or do not metabolize 10-OH-midazolam, ortho-OH-atorvastatin,
4-OH-alprazolam, 14-OH-clarithromycin. Neither are there asser-
tions indicating that these metabolites inhibit a drug-metabolizing
enzyme present in the system. The DIKB’s rule-based theory is
capable of predicting when inhibition of the parent compound will
or will not affect the formation of these metabolites but we did not
include these kinds of predictions in the study.
The missing interaction between itraconazole and erythromycin:
There were two evidence items in the system that supported the
assertion (erythromycin inhibits CYP3A4) [17,18] but no
assertion or evidence in the system claiming that itraconazole is
a substrate-of that enzyme. Hence, The system did not predict an
interaction between erythromycin and itraconazole with itraco-
nazole as the effected drug.
Conversely, the system had three default assumptions that sep-
arately established itraconazole to be both an in vivo and in vitro
selective inhibitor of CYP3A4 and erythromycin to be an in vitro
probe substrate. However, the system did not predict that itraco-
nazole would interact with erythromycin because it does not as-
sume that all properties established in vitro will hold in vivo. We
think that the decision to accept in vitro knowledge as sufﬁcient
for inferring an in vivo result should occur within the evidence-
model, not the rule-base.
4.4. Limitations
It’s important to note that our experiment only looked at binary
performance criteria—predictions were classiﬁed as ‘‘true” or
‘‘false” according to the validation set and the goal was to maxi-
mize ‘‘true” predictions and minimize ‘‘false” predictions. It is
likely that a different set of best-performing strategies would be
found if our goal was to optimize the accuracy of the system’s mag-
nitude predictions. This could be a worthwhile experiment because
the system is capable of order-of-magnitude predictions for some
drug combinations. As is shown in Section 3, the DIKB’s magnitude
estimates for 14 interactions using the drug-experts’ belief criteria
strategy corresponded with levels reported in clinical trial data
present in the validation set. A set of belief criteria strategies that
focused on optimizing magnitude would seek to expand the DIKB’s
coverage of known interactions past these 14 while still making
correct magnitude predictions. However, this kind of analysis
should also examine if there are some features of the rule-based
theory of metabolic inhibition interactions used by the DIKB that
could limit its ability to make accurate magnitude predictions.
The DIKB’s current method for magnitude estimation makes a
number of assumptions about many of the factors that can some-
times contribute to an increase in the AUC of an object drug in
pharmacokinetic DDI study. It might be desirable to apply a more
sophisticated approach that makes fewer assumptions such as that
described by Ohno et al. [19].
If a clinical trial is applied as support for an interaction or non-
interaction in the validation set while a labeling statement echo-
ing, but not citing, the study supports an assertion that the DIKB
uses to predict the same interaction, an assessment of the system’s
accuracy will be somewhat biased in favor of the system. The same
bias will exist if a validation-set interaction or non-interaction
rests on only a single non-traceable statement and there are asser-
tions in the DIKB used to predict the interaction or non-interaction
that depend on the study that inspired the statement Both situa-
tions have the same remedy—exclude the ‘‘dual-use” validation-
set interaction or non-interaction from calculations of the systems
accuracy. Unfortunately, we did not implement any strategy to
avoid this kind of bias so it is possible that some labeling datawas used to support mechanistic assertions that led to predictions
validated by the same data but appearing in a different source.
Future work will examine if this bias was present and, if so, what
effect removing the affected interactions or non-interactions has
on the calculations of DIKB accuracy.
Another limitation is that all case report evaluations were con-
ducted using a causality assessment tool (DIPS [3]) whose validity
and reproducibility has not yet been formally evaluated. Further-
more, the reviewer (co-investigator J.H.) was both the developer
of DIPS and a member of the DIKB evidence board. Future work
should involve a more rigorous evaluation of the DIKB’s novel
interactions designed to overcome any potential bias not ad-
dressed in this study.
5. Related work
Mechanism-based DDI prediction is currently part of pre-clini-
cal drug development where it used to identify potential interac-
tions between a new drug candidate and drugs currently on the
market [20]. These early-phase modeling efforts are geared to-
wards identifying interactions between a new drug and drugs with
which it might be co-administered early on, before much time and
money is invested [21,22]. The predictions made using drug mech-
anisms in this context are generally qualitative; they indicate that
two drugs might interact via a mechanism but offer no estimate of
the magnitude of the interaction. Scientists can use qualitative pre-
dictions to select the set of clinical trials necessary to establish a
new drug’s safety proﬁle [23].
Considerableeffort has been invested inboth industryandacade-
mia researching how to make quantitative estimates of in vivo DDIs
from in vitro evidence. Unfortunately, there is currently no general
method for making accurate quantitative estimates of the magni-
tude of a metabolic-inhibition DDI using in vitro data [23]. In spite
of its difﬁculties, software tools have been developed that combine
in vitro and in vivo ﬁndings to help clinicians reason about potential
metabolic DDIs [24,25]. These systems rely heavily onmathematical
models tomakequantitative estimates of themagnitudeof theirDDI
predictions. In contrast, the DIKB’s theory of metabolic DDIs makes
simple magnitude estimates based on qualitative assertions about
the degree to which inhibition of an enzyme would affect the clear-
ance of some drug. A comparison of the DIKB’s ability to accurately
predict magnitude with that of other systems would be worthwhile
and should be the topic of future work.
To the best of our knowledge the DIKB’s computational model
of evidence provides features that are unique among all current
system’s that represent drug-mechanism knowledge. While other
drug knowledge-bases and knowledge-based systems have linked
evidence to their drug facts (e.g. DRUGDEX6, Q-DIPS [24], Phar-
mGKB [26], and BioCyc [27]), only the DIKB classiﬁes all evidence en-
tered into the system using a biomedical evidence ontology oriented
toward conﬁdence assignment. This enables the system to provide
customized views of a body of drug-mechanism knowledge to users
who do not agree about the inferential value of particular evidence
types. This feature also allowed us to develop the novel approach
to identifying the optimal use of available evidence that we have
presented in this paper.
6. Conclusions
The results of the experiment discussed in this paper suggest that
the DIKB’s unique approach to representing evidence provides two
advantages over the representation methods used in current drug
knowledge-bases. One advantage of the method is that experts can
1002 R. Boyce et al. / Journal of Biomedical Informatics 42 (2009) 990–1003prospectively map their conﬁdence in each assertion type to some
arrangementof oneormoreabstract evidence types rather thanhav-
ing to reviewevery relevantevidence itemin thesystem.Theexperts
can thendeﬁnebelief criteria thatwill inﬂuence the prediction accu-
racy of the system in a predictable way. Relaxing belief criteria
causes the system to predict a larger number of true interactions,
sometimes at the expense of making more false predictions.
Another advantage of the method is that researchers can char-
acterize the prediction accuracy of a DDI theory using many differ-
ent sub-sets of a speciﬁc body of evidence. This process can
identify which evidence-use strategies optimize the system’s pre-
diction accuracy and coverage of known DDIs. While the resulting
evidence-use strategies might be unique to the set of drugs and
evidence items used to create them, it is reasonable that the clini-
cal relevance of any novel DDIs predicted using such ‘‘best-
performing” strategies will be within the range present for the
known interactions. This would have important implications for
drug safety and is an area we intend to explore in future work.
The experiment has also helped to identify an opportunity for
research into new computational methods to help support analysis
of belief criteria strategies. Currently, the task is difﬁcult because of
the complex interplay between the kinds of evidence present in the
knowledge-base, how it is linked to each assertion instance, and
the relationship between each assertion type and the variables
chosen for scoring the system’s prediction performance. In future
work we hope to explore this research area as well as validate
the DIKB’s approach to a broader range of drugs and drug-interac-
tion mechanisms. We also hope to explore methods for quantifying
the amount of conﬁdence that expert users should have in DDI pre-
dictions the system makes using LOEs that don’t meet belief crite-
ria. Progress on this topic might allow DIKB predictions to be
interpreted in terms of a normative decision-theoretic framework
such as expected utility theory. Understanding the relationship be-
tween the DIKB’s rank-ordered LOEs and quantitative measures of
evidential support such as those reviewed by Tentori et al. [28]
might be an important ﬁrst step in this direction.
We envision that, over the next decade, a new generation of
highly accurate tools will become available that use pharmacologic
theory, drug mechanism knowledge, and patient-speciﬁc data to
help clinicians assess the combined effect of multiple drugs, the ef-
fect of removing a drug from a patients drug regimen, and individ-
ual response to therapy due to enzyme polymorphisms. These
tools will be a signiﬁcant advance in medicine and a radical change
from the functionality that current prescribing software offers. Our
research on how to best represent drug mechanism knowledge for
the purpose of making clinically-relevant DDI predictions is a
small, through important step, toward understanding how to build
and deploy the highly accurate tools that we envision.
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